Table 2.
The amount of tumor-associated macrophages (TAMs) inversely correlates with overall survival in patients with recurrent glioblastoma (GBM).
| TAM Type/Location | Rho | P value |
|---|---|---|
| CD68+ bulk | −0.6382 | .040 |
| CD68+ infiltrative | −0.5379 | .094 |
| CD68+ normal | 0.1309 | NS |
| CD11b+ bulk | −0.5765 | .066 |
| CD11b+ infiltrative | −0.5606 | .076 |
| CD11b+ normal | N/A | N/A |
| CD163+ bulk | 0.1418 | NS |
| CD163+ infiltrative | 0.4119 | NS |
| CD163+ normal | 0.2474 | NS |
TAM scores were correlated with overall survival in patients with recurrent GBM who first received antiangiogenic treatment at recurrence. Patients with decreased survival had an increased number of CD68+ TAMs (P = .05) and CD11b+ cells (P = .04) in infiltrating tumor. Decreased survival was also seen in patients with increased number of CD11b+ TAMs in tumor bulk (P = .04).